Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Abstract Background In the management of urothelial carcinoma, patient selection for immunotherapy, particularly with immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1), is important for treatment efficacy. Inflammatory markers are useful for predicting treatment outcomes an...

Full description

Bibliographic Details
Main Authors: Meng Yang, Jingwen Zhang, Dongqun Wei, Tianyi Yu, Zeyu Chen, Xin Liu, Haitao Zhu
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Subjects:
Immunotherapy
Urothelial carcinoma
Inflammatory markers
Tislelizumab
Survival
Online Access:https://doi.org/10.1186/s12885-024-11969-5

Internet

https://doi.org/10.1186/s12885-024-11969-5

Similar Items